HOLLY SPRINGS, N.C. — FUJIFILM Diosynth Biotechnologies has signed a 10-year manufacturing agreement with Regeneron Pharmaceuticals, Inc., valued at over $3 billion, to ensure long-term U.S.-based production of Regeneron’s leading biologic medicines. The deal underscores both companies’ commitment to securing patient access to critical therapies as demand for biologics continues to grow.
Under the terms of the agreement, FUJIFILM Diosynth will manufacture Regeneron’s biologic treatments at its soon-to-be-operational large-scale biopharmaceutical facility in Holly Springs, North Carolina. The site, set to begin production later this year, is part of FUJIFILM’s broader $7 billion global expansion initiative, which includes adding new capacity in both the United States and Europe.
“This agreement with Regeneron demonstrates the trust our partners place in FUJIFILM Diosynth’s technical expertise and operational readiness,” said Toshihisa Iida, director and general manager of FUJIFILM Corporation’s Life Sciences Strategy Headquarters and Bio-CDMO Division. “We are investing heavily to bring additional capacity online in 2025, 2026, and beyond, ensuring that we can meet the evolving needs of the biopharmaceutical industry.”
The Holly Springs facility is a key component of FUJIFILM Diosynth’s kojoX™ manufacturing network, which employs standardized equipment and processes across global sites for greater supply chain security and efficient technology transfers. This modular approach will be leveraged in the new partnership to support Regeneron’s supply needs.
Lars Petersen, president and CEO of FUJIFILM Diosynth Biotechnologies, called the partnership with Regeneron a significant milestone. “Being chosen as a manufacturing partner by one of the world’s leading biotechnology companies is an honor. Our teams share a common vision of making transformative medicines accessible to patients, and this collaboration enables us to deliver capacity faster and ensure supply continuity.”
Daniel Van Plew, executive vice president and general manager of Industrial Operations and Product Supply at Regeneron, emphasized the importance of the partnership for sustaining the company’s impact in treating serious diseases. “We are committed to producing innovative therapeutics that help treat or even cure devastating conditions,” he said. “This collaboration with FUJIFILM Diosynth reflects our confidence in their ability to meet our rigorous standards and support our growth.”
The agreement reflects FUJIFILM’s broader strategy to expand its presence in the U.S., the world’s largest biopharmaceutical market. The company has invested approximately $4 billion in U.S. manufacturing infrastructure, life sciences capabilities, and workforce development. In North Carolina alone, FUJIFILM Diosynth has already created 500 new positions, with a target of 1,400 jobs by 2031 as part of its long-term growth plan.
The partnership marks a significant step in enhancing U.S.-based manufacturing capacity for biologics, ensuring a robust supply chain for essential medicines that treat millions of patients worldwide.
